Inspire Investing LLC Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Inspire Investing LLC increased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 15.0% during the second quarter, Holdings Channel.com reports. The institutional investor owned 17,290 shares of the company’s stock after buying an additional 2,258 shares during the quarter. Inspire Investing LLC’s holdings in Syndax Pharmaceuticals were worth $355,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in SNDX. nVerses Capital LLC purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at $33,000. Quadrant Capital Group LLC grew its holdings in shares of Syndax Pharmaceuticals by 158.3% during the fourth quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock valued at $53,000 after buying an additional 1,496 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Syndax Pharmaceuticals by 28.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock valued at $171,000 after buying an additional 1,587 shares during the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock valued at $187,000 after buying an additional 1,312 shares during the last quarter. Finally, American Century Companies Inc. purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at $201,000.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Bank of America boosted their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. JPMorgan Chase & Co. lowered their price target on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus upped their price target on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. HC Wainwright upped their price target on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Finally, Scotiabank lowered shares of Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, June 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $35.33.

Syndax Pharmaceuticals Stock Down 1.9 %

SNDX opened at $18.27 on Friday. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.22 and a twelve month high of $25.34. The company has a 50-day moving average price of $20.71 and a 200 day moving average price of $21.16. The company has a market cap of $1.55 billion, a PE ratio of -5.67 and a beta of 0.91.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. During the same period in the previous year, the business posted ($0.64) EPS. The firm’s revenue was up 3499999990.0% on a year-over-year basis. As a group, sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).